140 related articles for article (PubMed ID: 31377969)
1. Vemurafenib may overcome TNF-related apoptosis-inducing ligand (TRAIL) resistance in anaplastic thyroid cancer cells.
Pilli T; Cantara S; Marzocchi C; Pacini F; Prabhakar BS; Castagna MG
Endocrine; 2020 Jan; 67(1):117-123. PubMed ID: 31377969
[TBL] [Abstract][Full Text] [Related]
2. S100A4 Knockout Sensitizes Anaplastic Thyroid Carcinoma Cells Harboring BRAFV600E/Mt to Vemurafenib.
Jiao X; Zhang H; Xu X; Yu Y; Zhang H; Zhang J; Ning L; Hao F; Liu X; Niu M; Chen CT; Chen D; Zhang K
Cell Physiol Biochem; 2018; 49(3):1143-1162. PubMed ID: 30196299
[TBL] [Abstract][Full Text] [Related]
3. Signal transducer and activator of transcription 3 inhibition alleviates resistance to BRAF inhibition in anaplastic thyroid cancer.
Wang Y; Hu Z; Ma W; Niu Y; Su J; Zhang L; Zhao P
Invest New Drugs; 2021 Jun; 39(3):764-774. PubMed ID: 33245464
[TBL] [Abstract][Full Text] [Related]
4. MADD silencing enhances anti-tumor activity of TRAIL in anaplastic thyroid cancer.
Saini S; Sripada L; Tulla K; Qiao G; Kunda N; Maker AV; Prabhakar BS
Endocr Relat Cancer; 2019 Jun; 26(6):551-563. PubMed ID: 30999276
[TBL] [Abstract][Full Text] [Related]
5. Suppression of AKT Potentiates Synergistic Cytotoxicity of Apigenin with TRAIL in Anaplastic Thyroid Carcinoma Cells.
Kim SH; Kang JG; Kim CS; Ihm SH; Choi MG; Yoo HJ; Lee SJ
Anticancer Res; 2015 Dec; 35(12):6529-37. PubMed ID: 26637867
[TBL] [Abstract][Full Text] [Related]
6. Valproic acid sensitizes TRAIL-resistant anaplastic thyroid carcinoma cells to apoptotic cell death.
Cha HY; Lee BS; Kang S; Shin YS; Chang JW; Sung ES; Kim YS; Choi JW; Kim JH; Kim CH
Ann Surg Oncol; 2013 Dec; 20 Suppl 3():S716-24. PubMed ID: 23982257
[TBL] [Abstract][Full Text] [Related]
7. Synergistic effect of metformin and vemurufenib (PLX4032) as a molecular targeted therapy in anaplastic thyroid cancer: an in vitro study.
Durai L; Ravindran S; Arvind K; Karunagaran D; Vijayalakshmi R
Mol Biol Rep; 2021 Nov; 48(11):7443-7456. PubMed ID: 34716862
[TBL] [Abstract][Full Text] [Related]
8. Potential of the dual mTOR kinase inhibitor AZD2014 to overcome paclitaxel resistance in anaplastic thyroid carcinoma.
Milošević Z; Banković J; Dinić J; Tsimplouli C; Sereti E; Dragoj M; Paunović V; Milovanović Z; Stepanović M; Tanić N; Dimas K; Pešić M
Cell Oncol (Dordr); 2018 Aug; 41(4):409-426. PubMed ID: 29790111
[TBL] [Abstract][Full Text] [Related]
9. Proteasome inhibitors synergize with tumor necrosis factor-related apoptosis-induced ligand to induce anaplastic thyroid carcinoma cell death.
Conticello C; Adamo L; Giuffrida R; Vicari L; Zeuner A; Eramo A; Anastasi G; Memeo L; Giuffrida D; Iannolo G; Gulisano M; De Maria R
J Clin Endocrinol Metab; 2007 May; 92(5):1938-42. PubMed ID: 17327374
[TBL] [Abstract][Full Text] [Related]
10. Role of autophagy in the resistance to tumour necrosis factor-related apoptosis-inducing ligand-induced apoptosis in papillary and anaplastic thyroid cancer cells.
Jin SM; Jang HW; Sohn SY; Kim NK; Joung JY; Cho YY; Kim SW; Chung JH
Endocrine; 2014 Mar; 45(2):256-62. PubMed ID: 23821365
[TBL] [Abstract][Full Text] [Related]
11. Targeting PEAK1 sensitizes anaplastic thyroid carcinoma cells harboring BRAF
Wang Q; Hao F; Ning L; Sun C
Histol Histopathol; 2024 Jan; ():18705. PubMed ID: 38284248
[TBL] [Abstract][Full Text] [Related]
12. Expression of angiogenic switch, cachexia and inflammation factors at the crossroad in undifferentiated thyroid carcinoma with BRAF(V600E).
Husain A; Hu N; Sadow PM; Nucera C
Cancer Lett; 2016 Oct; 380(2):577-585. PubMed ID: 26189429
[TBL] [Abstract][Full Text] [Related]
13. Effects of nutraceuticals on anaplastic thyroid cancer cells.
Allegri L; Rosignolo F; Mio C; Filetti S; Baldan F; Damante G
J Cancer Res Clin Oncol; 2018 Feb; 144(2):285-294. PubMed ID: 29197967
[TBL] [Abstract][Full Text] [Related]
14. TRAIL-induced apoptosis of thyroid cancer cells: potential for therapeutic intervention.
Ahmad M; Shi Y
Oncogene; 2000 Jul; 19(30):3363-71. PubMed ID: 10918593
[TBL] [Abstract][Full Text] [Related]
15. R-roscovitine sensitizes anaplastic thyroid carcinoma cells to TRAIL-induced apoptosis via regulation of IKK/NF-kappaB pathway.
Festa M; Petrella A; Alfano S; Parente L
Int J Cancer; 2009 Jun; 124(11):2728-36. PubMed ID: 19230027
[TBL] [Abstract][Full Text] [Related]
16. Unusually long-term responses to vemurafenib in BRAF V600E mutated colon and thyroid cancers followed by the development of rare RAS activating mutations.
Ofir Dovrat T; Sokol E; Frampton G; Shachar E; Pelles S; Geva R; Wolf I
Cancer Biol Ther; 2018; 19(10):871-874. PubMed ID: 30036146
[TBL] [Abstract][Full Text] [Related]
17. Use of vemurafenib in anaplastic thyroid carcinoma: a case report.
Marten KA; Gudena VK
Cancer Biol Ther; 2015; 16(10):1430-3. PubMed ID: 26176686
[TBL] [Abstract][Full Text] [Related]
18. Sorafenib and Quinacrine Target Anti-Apoptotic Protein MCL1: A Poor Prognostic Marker in Anaplastic Thyroid Cancer (ATC).
Abdulghani J; Gokare P; Gallant JN; Dicker D; Whitcomb T; Cooper T; Liao J; Derr J; Liu J; Goldenberg D; Finnberg NK; El-Deiry WS
Clin Cancer Res; 2016 Dec; 22(24):6192-6203. PubMed ID: 27307592
[TBL] [Abstract][Full Text] [Related]
19. Role of Krüppel-Like Factor 4 in the Maintenance of Chemoresistance of Anaplastic Thyroid Cancer.
Lee SI; Kim DK; Seo EJ; Choi EJ; Kwon YW; Jang IH; Lee JC; Kim HY; Shong M; Kim JH; Kim SJ
Thyroid; 2017 Nov; 27(11):1424-1432. PubMed ID: 28920531
[TBL] [Abstract][Full Text] [Related]
20. Thyroid carcinoma cells are resistant to FAS-mediated apoptosis but sensitive to tumor necrosis factor-related apoptosis-inducing ligand.
Mitsiades N; Poulaki V; Tseleni-Balafouta S; Koutras DA; Stamenkovic I
Cancer Res; 2000 Aug; 60(15):4122-9. PubMed ID: 10945619
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
